Organoid, Fibroblast, and Immune Cell
Co-Culture

Versatile Organoid Co-Culture Platform for Patient-Relevant In Vitro Drug Development

A tailor-made reconstituted tumor microenvironment (TME) co-culture platform capable of combining tumor organoids of interest, fibroblasts and immune cells e.g. T cells, Monocytes, M1 and M2 macrophages.

This platform is well-suited for therapeutics targeting the TME including immunotherapy,TME specific drug delivery, fibroblast modulation, immune re-activation and recruitment.

Use our unique organoid co-culture platform to benefit from:

• Unique organoid models, exclusively developed using Hubrecht Organoid Technology (HUB) protocols
• Co-culture with fibroblasts to more closely resemble patient pathology
• Higher throughput evaluation and faster results compared with humanized in vivo PDX models
• An easily scalable platform, with multiple tumor organoids, fibroblasts, and immune cell donor combinations tested simultaneously
• Organoids from both tumor and healthy tissue to evaluate off target effects
• A large library of tumor models including spheroids reflecting the patient population heterogeneity and antigen expression

Harness Our Versatile Organoid Co-Culture Platform For a Variety of Studies Targeting the TME

Our organoid co-culture platform is available to:

• Evaluate the potency of your immunotherapies using allogenic T cell assays with optimized conditions
• Screen and evaluate the efficacy of different immunotherapeutic approaches
• Test multiple treatment strategies on patient derived organoids
• Study the specific interactions between immune cells, cancer cells, stromal cells
• Investigate the effectiveness of test agents that directly target fibroblasts in a pathology resembling in vitro model.
• Study drug mode-of action and resistance in a tailor-made reconstituted TME
• Assess tumor organoid killing by allogenic T cells and CAR-T cells, or to test ADCC and ADCP effects
• Evaluate tumor reactivity of CAR-T and TCR cells
• Profile immunotherapy target gene expression on tumor organoids or identify antigens of interest (e.g. tumor-associated antigens, immune checkpoint molecules)

Develop Unique New Models through Organoid Engineering

Organoids and fibroblasts can be genetically engineered to express your desired biomarker, immunotherapy target or to detect tumor organoid killing by (immune-) fluorescent imaging.

About HUB Tumor Organoids

Tumor organoids are developed directly from patient tumors and matched healthy tissue using patented and exclusive HUB technology. Our well-characterized and ample patient-derived xenograft (PDX) collection is also available as an alternative source of human tumor tissue. PDX models allow additional tumor organoid development across more indications and to truly represent patient population diversity for biomarker identification and hypothesis generation.